Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FYU-981 in Renal Insufficiency
NCT02347046Phase 1Completed
- Sponsor
- Fuji Yakuhin
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (3 arms), sponsored by Fuji Yakuhin. Primary endpoints: Maximum plasma concentration at 48 hours, Time to reach peak plasma concentration at 48 hours and 8 more. Started Jan 2015; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02347046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347046.